Latest / This Week In Medicine
May 2026 Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cance
This study evaluates the clinical potential of daraxonrasib, a novel oral medication designed to inhibit the RAS mutations that drive growth in over 90% of pancreatic cancers. By targeting the active "on" state of these proteins, the drug demonstrated significant antitumor activity in patients whose cancer had progressed after previous treatments, showing particularly promising objective response rates and survival metrics in those with specific genetic variants. While the therapy effectively hindered tumor progression, researchers noted a high frequency of treatment-related adverse…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.